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Abstract
NMDA autoantibody encephalitis presenting as schizophrenia suggests the possible role of adaptive cell-mediated
immunity in idiopathic schizophrenia. However, to our knowledge there have been no trials of the immune-
suppressant methotrexate in schizophrenia. We tested if low-dose methotrexate as used in the treatment of systemic
autoimmune disorders would be tolerable and effective in people with schizophrenia in a feasibility study. Ninety-two
participants within 5 years of schizophrenia diagnosis were recruited from inpatient and outpatient facilities in Karachi,
Pakistan. They were randomised to receive once weekly 10-mg oral methotrexate (n= 45) or matching placebo (n=
47) both with daily 5-mg folic acid, in addition to treatment as usual for 12 weeks. There were eight dropouts per
group. Side effects were non-significantly more common in those on methotrexate and were not severe. One person
developed leukopenia. Positive symptom scores improved more in those receiving methotrexate than placebo (β=
−2.5; [95% CI −4.7 to −0.4]), whereas negative symptoms were unaffected by treatment (β=−0.39; [95% CI −2.01 to
1.23]). There were no immune biomarkers but methotrexate did not affect group mean leucocyte counts or C-reactive
protein. We conclude that further studies are feasible but should be focussed on subgroups identified by advances in
neuroimmune profiling. Methotrexate is thought to work in autoimmune disorders by resetting systemic regulatory T-
cell control of immune signalling; we show that a similar action in the CNS would account for otherwise puzzling
features of the immuno-pathogenesis of schizophrenia.
Introduction
A number of findings suggest that inflammatory pro-
cesses are involved in the pathogenesis of schizophrenia.
Many studies report raised circulating cytokine and C-
reactive protein (CRP) concentrations in patients with
schizophrenia1. Meta-analyses confirm that acutely ill
patients with schizophrenia have raised plasma
concentrations of CRP and classic inflammatory cytokines
such as IL-6 and TNF-α in comparison with non-
psychotic samples2. These findings have led to much
interest in the possibility that peripheral changes might
induce or reflect inflammatory changes in the brain that
could be reversed by anti-inflammatory drugs. Other
studies suggest that autoimmune mechanisms may be at
play. Epidemiological studies report that patients with
schizophrenia and their relatives have an increased risk of
autoimmune disorders such as systemic lupus erythema-
tosus and psoriasis3. More directly, encephalitis with
autoantibodies against the NMDA glutamate receptor can
present as schizophrenia4, however, such antibodies are
not common in sporadic schizophrenia5. Nevertheless,
genetic loci in the major histocompatibility complex are
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clearly associated with psychosis risk, and genes in this
region regulate cell-mediated immune mechanisms of the
adaptive immune system and mechanisms of
autoimmunity6.
These lines of evidence have led researchers to inves-
tigate the adjunctive use of anti-inflammatory agents in
the treatment of schizophrenia. In a meta-analysis, two
studies of aspirin in 136 patients found that positive
symptoms improved with the addition of aspirin com-
pared to antipsychotic treatment alone7. However, the
selective COX-2 inhibitor celecoxib showed no overall
benefit on symptoms. The antibiotic minocycline has
known anti-inflammatory effect in autoimmune disorders
such as systemic lupus erythematosus and rheumatoid
arthritis, although it is used infrequently today. Further-
more, minocycline is known to reduce the inflamed state
of peripheral macrophages and their brain-resident
equivalents, microglia8. A number of small clinical trials
have reported that minocycline improves negative symp-
toms when added to treatment as usual (TAU) in schi-
zophrenia, including our proof of concept 2-centre study
in Pakistan and Brazil8. However, in a definitive follow-up
UK study in 207 patients with recent onset psychosis, we
found no benefit of minocycline after 8 or 52 weeks of
treatment9. The reasons for the discrepant findings are
not clear but another large study in 200 patients with
established illness also reported no benefit of minocy-
cline10. In the UK study, plasma cytokine levels did not
predict outcome and did not change over the course of
treatment. Magnetic resonance imaging (MRI) revealed
no decreases in grey matter to suggest neuropathic
changes over 12 months in the placebo group. There was
thus little evidence, albeit indirect, of an active neuroin-
flammatory process in the patient sample. More directly, a
number of positron emission tomography (PET) studies
in patients at various stages of schizophrenia now report
no increase in radioligand binding to the translocator
protein (TSPO), which is a biomarker for activated
microglia11. Our recent study found that reductions in
TSPO binding in schizophrenia, which we hypothesised,
are an indication that microglia are in a non-inflamed
phagocytic mode driven by astrogliosis12. These findings
together with large scale transcriptomic evidence in post-
mortem brain, discussed below, suggest that microglial
inflammation may not be central to pathogenesis in
schizophrenia, hence the lack of efficacy of minocycline.
We carried out a trial to test the feasibility of evaluating
the efficacy of methotrexate, a potent immune-
suppressant drug that acts on cell-mediated adaptive
immunity with indirect anti-inflammatory actions on the
innate immune system. At high doses (up to a gram/dose)
the anti-folate actions of methotrexate mediate its anti-
proliferative effects through inhibition of purine and
pyrimidine synthesis. However this mechanism is
minimised by the use of low doses (7.5–25mg/week)
combined with folate supplements in routine therapy for
autoimmune disorders such as rheumatoid arthritis and
psoriasis13. These disorders are associated with impaired
control of the immune response by circulating regulatory
T cells (Tregs) and thus a pro-inflammatory balance in
functional T-cell populations and in the pattern of cyto-
kine secretion14,15. Methotrexate restores impaired Treg
function in-vitro and during treatment for example,
through resetting epigenetic control of FoxP3 expression,
the master regulator of Treg function16. Methotrexate is
known to increase tissue levels of adenosine, a potent
anti-inflammatory molecule, and this is also mediated by
Tregs14. These actions restore an anti-inflammatory
cytokine profile in autoimmune diseases3,17. Given the
well-known comorbidity and shared familial risk between
schizophrenia and autoimmune disorders18,19, the possi-
ble antipsychotic efficacy of methotrexate is of consider-
able aetiological significance for schizophrenia. We report
the first trial evaluating the feasibility and efficacy of
methotrexate added to TAU in patients with early schi-
zophrenia spectrum disorders within 5 years of onset—
when neuroinflammation might still be active with less
exposure to antipsychotic drugs. The results have been
published in abstract form and we are not aware of other
trials of methotrexate in patients with psychotic illness20.
Methods
Study design and participants
We conducted a randomised, double blind, placebo-
controlled exploratory trial of methotrexate 10mg once a
week added to TAU for patients with schizophrenia,
schizoaffective disorder, psychosis not otherwise specified
and schizophreniform disorder. The trial was registered
on Clinicaltrial.gov (NCT02074319) on February 28, 2014.
The final protocol and the feasibility and statistical ana-
lysis plan were published in 201521.
The study was completed between December 2013 and
August 2015 at four major hospitals in Karachi, Pakistan.
The Pakistan Institute of Living and Learning indepen-
dent Ethics Committee approved the study (Project
Reference: PILL/SMRI/12627). The study was conducted
in accordance with the principles of the Declaration of
Helsinki. All patients gave their written, informed consent
prior to enrolment in the study.
Participants were recruited from inpatient and out-
patient psychiatric departments. Participants between the
ages of 18 and 35 years, meeting the Diagnostic and Sta-
tistical Manual-IV (DSM-IV) criteria for schizophrenia,
schizoaffective disorder, psychosis not otherwise specified
or schizophreniform disorder and within the first 5 years
of diagnosis were eligible to take part in the study. All
participants included in the trial were on stable
medication for 4 weeks prior to baseline assessments.
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Female participants were included in the study if they
agreed to continue adequate contraception during the trial.
Exclusion criteria included: organic brain disease or a
neurological diagnosis; significant renal or hepatic
impairment; pre-existing blood dyscrasias (marrow
hypoplasia, leukopenia, thrombocytopenia or anaemia);
DSM-IV criteria for substance misuse in the previous
6 months (other than nicotine) or use of psychotropic
drugs of abuse in the prior month (other than nicotine);
pregnant or lactating women and those of reproductive
age but not using adequate contraception.
Treating clinical teams initially identified and approa-
ched potential participants meeting entry criteria for the
trial, provided a patient information leaflet about the
study and offered to arrange a visit from the research
team to explain the study in more detail. Potential parti-
cipants were given at least 24 h after the detailed expla-
nation by a member of the research team before they
made a decision on whether to give signed consent to
participate in the study and to provide consent for access
to participant medical records.
Randomisation and masking
Participants were allocated to active methotrexate or
matching placebo according to a randomised permuted
blocks algorithm with stratification by treating hospital
site. Patients were allocated to either methotrexate or
placebo according to pseudo-random sequence generated
by the trial statistician in Manchester to produce roughly
equal groups. The details of the allocation were concealed
from the research team until all data collection had been
completed. The study pharmacist dispensed the medica-
tion on a fortnightly basis. In the event of a medical
emergency, only the trial pharmacist or deputy had access
to the treatment allocation list for unblinding and this
would only proceed if the chief investigator or his deputy
authorised it.
Patients took trial medication of methotrexate 10mg
orally once a week or matching placebo for the duration
of the trial (12 weeks). All participants in both arms of the
trial also took folic acid 5 mg/day orally for 6 days a week
except the day that trial medication (methotrexate or
placebo) was given. No restrictions were placed on med-
ication changes (type or dose), though stability in medi-
cation regime was encouraged. TAU consisted of first- or
second-generation antipsychotic medication, as deemed
suitable by their responsible psychiatrist. There was
minimal access to formal psychological therapies. The
consultant psychiatrist for each participant remained
responsible for his or her clinical care.
Procedures
The schedule of assessments is detailed in the published
protocol21. At screening, the trained research assistants
(RAs) confirmed diagnostic criteria on the basis of the
Structured Clinical Interview for DSM-IV. Urine was
obtained for pregnancy tests. At the randomisation visit,
all baseline symptomatic, cognitive and functional efficacy
measures were recorded, together with assessments of
side effects and medication adherence. Symptomatic
measures, side effects and adherence assessments were
repeated at follow-up visits at 2, 4, 8 and 12 weeks. Even
low-dose methotrexate can have serious side effects22 and
we monitored signs of toxicity with a checklist based on
UK guidelines23. We checked haematological measures,
renal function, liver function and routine CRP at baseline,
2, 4, 6 and 12 weeks. At 12 weeks, the baseline cognitive
tasks and measures of functioning and quality of life were
repeated. Project RAs had regular training and harmoni-
sation discussions at 2-weekly teleconferences and at
6 monthly away days.
The trial was monitored by an independent Trial
Steering Committee (TSC) that included a senior physi-
cian and a service user. The TSC also had the responsi-
bility for data monitoring to oversee any potential harm to
the participants from taking part in the trial.
Outcomes
The feasibility outcomes were recruitment and reten-
tion rates, a checklist of common side effects experienced
with methotrexate, and adherence (pill check) to the trial
medication. We measured efficacy using the positive and
negative symptom subscale scores and the total score on
the Positive and Negative Syndrome Scale (PANSS)24.
Efficacy outcomes also included assessments of func-
tioning: Global Assessment of Functioning (GAF)25;
Schedule of Assessment for Insight (SAI)26; Clinical
Global Impression Scale (CGI)27; EuroQol-5D (EQ-5D)28
and the Social Functioning Scale (SFS)29. Cognition was
assessed using “pencil and paper tests” and CogState30.
The assessments included processing speed, attention/
vigilance, working memory (nonverbal and verbal), verbal
learning, visual learning, reasoning and problem solving
and social cognitions. These assessments covered all
seven domains recommended by MATRICS (NIMH
initiative)31. Adverse effects were monitored using a
checklist specifically designed for methotrexate.
Statistical analysis
There are no studies available concerning the effect of
methotrexate added to TAU in early schizophrenia to
inform an optimal sample size. The primary aim of this
study was to determine acceptability and tolerability of
methotrexate added to TAU but we also aimed to provide
efficacy data to better estimate the sample size for future
trials. Our sample size consideration was based on
the hypothesis that there is a significant difference on the
clinical outcome measures (e.g., PANSS) and the cognitive
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function measures from baseline to end point between the
methotrexate group and TAU group. The sample size was
calculated to detect a group difference at p < 0.20 due to
the exploratory nature of the study. With 32 participants
per group, this study would have 80% power to detect a
medium standardised effect size of 0.53. The estimated
loss to follow-up rate was 10% and, therefore, a total of 72
patients (36 methotrexate, 36 TAU) were needed.
Differences between treatment groups for the final 12-
week clinical outcome measures and cognitive function
measures were analysed using analysis of covariance, with
baseline measures as covariates, as described in the pub-
lished protocol21. Outcomes with strongly positively
skewed distributions were log-transformed. In the sec-
ondary planned analysis, we analysed the repeated clinical
outcome measures at baseline, 2, 4, 8 and 12 weeks using
generalised estimating equations (GEE) to estimate the
effect of treatment on longitudinal outcomes, including
baseline values and time terms as covariates taking
account of the within-subject correlation in longitudinal
data using SAS 9.4 (SAS Institute Inc., Cary, North Car-
olina, USA). Multiple imputation was used to address the
influence of missing values on outcome using all data
from all 92 randomised participants in an intention to
treat sensitivity analysis based on the multivariate normal
distribution method32. Thirty imputed samples were
created per missing final value and analysed simulta-
neously using Stata version 15.1. The occurrence of side




We approached 421 participants from December 2013.
The date of first randomisation was January 2014 and the
last visit was completed in June 2015. These participants
were then assessed for eligibility to take part in the trial
(Fig. 1). Of these, 289 were excluded as they did not fulfil
the inclusion criteria, 8 were not willing to take part, 12
were planning on moving away from the city and 20 were
not contactable following the initial screening visit. This
left 92 participants who were randomly allocated to either
receive methotrexate (n= 45) or placebo (n= 47), in
addition to TAU. Recruitment continued for longer than
initially planned, as dropouts were higher than expected.
Seventy-six participants completed the study, 39 in the
placebo arm and 37 in the methotrexate arm, slightly
overshooting the 32 per arm target. The retention rate in
both arms was ~80%. There were an equal number of
dropouts in both groups (n= 8). Following randomisation
eight participants discontinued the TAU arm, with three
participants uncontactable, three migrating and two
families refusing to continue with the trial. In the meth-
otrexate arm, five participants were uncontactable, two
families refused to continue with the study, and one
participant refused their TAU medication.
Baseline characteristics
The baseline characteristics were similar in the inter-
vention and control groups (Table 1). The mean (SD) age
of participants was 24.8 (4.2) years in the treatment arm
and 26.6 (4.9) years in the control group. All were out-
patients. There was a male predominance in both groups
with ~78% males in the intervention arm and 68% in the
placebo. Educational attainment in both arms was limited
to 6 or 7 years in both groups. The majority (72%) of
participants were single. Diagnosis in over half of both
groups, according to DSM-IV criteria, was paranoid
schizophrenia. Twelve people had disorganised, residual
or schizoaffective subtypes and most (n= 10) were allo-
cated to placebo, they were eliminated in a secondary
analysis below. The mean total PANSS was in the
mild–moderate range for both groups; methotrexate
group 65 and placebo 59. CGI severity scores at baseline
also did not show any significant group difference. All but
five patients were on risperidone or olanzapine and
treatments were evenly distributed between the groups
(Table ST1).
Clinical and cognitive outcomes
Both groups showed an improvement on all the major
clinical outcomes during the study (Fig. 2). The total PANSS
scale score dropped by 30% in the methotrexate group and
Assessed for eligibility =
421
Inclusion criteria negative = 289
Patient planning to move away = 12
Family not willing = 8
Loss of contact = 20
Randomized = 92
Patients allocated to 
Placebo group = 47
Patients allocated to 
Methotrexate group = 45
Discontinued Placebo = 8
Not contactable = 3
Non cooperative family = 2
Migrated = 3
Analyzed = 39
Discontinued Methotrexate = 8
Not contactable = 5
Non cooperative family = 2
Refused TAU Medication = 1
Analyzed = 37
Fig. 1 Patient flow through the study. Consort diagram.
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18% in the placebo group. Methotrexate had a statistically
significant effect on PANSS Positive Subscale (p= 0.02) and
GAF Scale (p= 0.03). There was a trend indicative of
improvement in PANSS General Psychopathology Subscale
(p= 0.06) and PANSS total score was of borderline sig-
nificance (p= 0.05). There was no statistically significant
effect on PANSS negative subscale, CGI, EQ-5D, SAI or SFS.
However, on the six social domains of the SFS,
methotrexate-associated improvement was seen in pro-
social activities (p= 0.03), recreational activities (p= 0.06)
and interpersonal behaviour (p= 0.08) but with no numeric
benefit on performance of living skills or on social engage-
ment (Table ST2). The treatment effects are summarised in
Table 2. There were no statistically significant effects of
treatment on the cognitive parameters (Table 3). There was
no statistically significant change in white cell count or CRP
between the two groups (Table 2). The results were con-
firmed by the GEE analysis using all the intermediate
PANSS scores, with a slightly greater treatment effect of
−2.94 (95% CI −5.10, −0.77) and significance level
(p= 0.008) for the PANSS positive scores and no significant
change in PANSS negative scores −0.74 (−2.36, 0.87),
p= 0.366. The group difference remained statistically sig-
nificant in the ITT sensitivity analysis (−2.2 (95% CI:−4.5 to
0.0); p= 0.049). We repeated the efficacy analysis excluding
the 12 participants with disorganised, residual or schi-
zoaffective subtypes; the efficacy of methotrexate remained
unchanged (−2.52 (95% CI: −4.9 to 0.09); p= 0.042).
Adherence and tolerability
In the study, there were no statistically significant differ-
ences in the methotrexate-related side effect checklist
between groups. The greatest group difference was nausea
occurring in 19.1% of the methotrexate group and 6.7% of
the placebo group (Table 4). Dry cough occurred in 10.6%
with methotrexate and 4.4% placebo. Oral ulceration and
sore throat were more common in the placebo group than
those on methotrexate. One participant taking methotrex-
ate developed probable treatment-related symptoms and
was later found to have non-critical leukopenia but they had
moved and were lost to follow-up. Mean leucocyte count
did not change significantly in either group. There were no
other adverse reactions or events and no clinically sig-
nificant abnormalities on renal or hepatic function tests
emerged for any of the participants. Eight participants
withdrew from each arm but all eight of the placebo group
withdrew or were lost to follow up before taking trial
medication whereas 5/8 in the methotrexate group dropped
out after taking trial treatment, two after 2 weeks (i.e., two
doses), one after 4 weeks and two after 8 weeks.
Discussion
We report on the first randomised study to assess the
feasibility, tolerability and efficacy of methotrexate in
patients with schizophrenia. Recruitment was satisfactory
from a population of patients in contact with clinical
teams and taking antipsychotic drugs. Approximately 70%
of those eligible agreed to participate. Our estimated
dropout rate of 10% based on our previous studies proved
optimistic, nevertheless retention at 82% over 12 weeks
compares favourably with antipsychotic drug trials33.
Furthermore, dropouts were unrelated to reported side
effects although poor tolerability may have contributed to
the five dropouts from the methotrexate group that
occurred after starting trial medication. Nevertheless, the
recruitment, retention and tolerability data suggest that a
larger study is feasible at the low 10-mg dose. One case of
non-critical leukopenia was detected after two doses and





Mean (SD) Mean (SD)
Age (years) 24.8 (4.2) 26.6 (4.9)
Education (years) 5.7 (4.0) 7.0 (4.0)
Clinical Global Impression
(CGI)
4.5 (0.8) 4.4 (0.8)
PANSS (subscale scores)
Positive symptoms 18.0 (5.9) 15.7 (6.3)
Negative symptoms 16.4 (4.4) 15.0 (3.7)
General
psychopathology
30.4 (7.8) 28.4 (4.9)
Total score 64.8 (15.1) 59.0 (11.4)
N (%) N (%)
Sex
Male 35 (77.8) 32 (68.1)
Female 10 (22.2) 15 (31.9)
Marital Status
Single 29 (64.4) 37 (78.7)
Married 15 (33.3) 9 (19.2)
Separated 0 (0.0) 1 (2.1)
Divorced 1 (2.2) 0 (0.0)
Diagnosis of SCID
Paranoid type 32 (71.1) 28 (59.6)
Disorganised type 2 (4.4) 6 (12.8)
Undifferentiated type 11 (24.4) 9 (19.1)
Residual type 3 (6.4)
Schizoaffective disorder 1 (2.1)
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this is a recognised occurrence with low-dose metho-
trexate. Neutropenia in patients receiving low-dose
methotrexate ranges from 1.4–7% in trials of inflamma-
tory rheumatic disease34. Attrition rates of up to 15% have
been reported due to leukopenia, liver function test dys-
crasia and/or gastrointestinal side effects and would need
to be factored into trial design with equivalent doses35.
Methotrexate appeared to exert a selective benefit on
positive symptoms in early schizophrenia with no effect on
negative symptoms or on cognitive performance but with an
overall improvement in general and total symptoms and in
general functioning. The study was not primarily designed to
detect the efficacy of methotrexate but the effects were sta-
tistically significant and robust to examination for confounds
such as baseline differences or differential dropouts. The
groups were well-matched demographically and in terms of
antipsychotic treatment. It seems unlikely that the finding is
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Fig. 2 Mean clinical outcome trajectories by randomisation group.
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plasma levels of antipsychotics; methotrexate is excreted
largely unchanged and so does not block or induce CYP450
enzymes that metabolise antipsychotic drugs36. However,
future studies could consider monitoring drug concentra-
tions. There was no effect on the mild–moderate negative
symptoms as measured by the PANSS subscale nor on tests
of cognition. However, the mostly borderline improvements
on social and recreational activity could be an indicator of
possible benefit in patients with severe negative symptom
impairments especially with evidence of immune dysfunc-
tion. There is weak evidence that folic acid (taken by all
participants) decreases negative symptoms and this might
have obscured a small group difference37. A much larger trial
would be necessary to have a high probability of repeating
our finding on positive symptoms but this would not
increase the magnitude of the small clinically unimportant
placebo-drug difference. The patients in this study had mild
to moderately severe symptoms and studies in more severely
ill patients are more likely to reveal definitive efficacy. Fur-
thermore, we used the lowest clinically effective dose in
autoimmune disorders, which often needs to be increased
and greater doses might also produce greater effects in
schizophrenia. However, the health risks of methotrexate are
substantial and require careful monitoring, which would rule
out large unfocussed trials of greater potentially more
effective doses in schizophrenia.
Low-dose methotrexate is a standard treatment in a
number of autoimmune disorders that share risk with
schizophrenia18. The possible efficacy of methotrexate in
both disorders, even if very partial in schizophrenia, sug-
gests that they may share aspects of pathogenesis. In
autoimmune disorders it is clear that dysfunctional Tregs
fail to control immune activation15; a similar dysfunction in
schizophrenia would account for the systemic low-grade
inflammation associated with schizophrenia in studies of
peripheral hsCRP and cytokines38. Indeed evidence for Treg
cell dysfunction is beginning to appear; FoxP1 (critical for
Treg function) is a GWAS schizophrenia risk gene39 and
Treg cells from 40 patients showed a substantial functional
impairment as in autoimmune disorders40. Treg cells in
health occur in the meninges and brain lymphatics and have
an important role in immune tolerance and surveillance41.
Table 2 Clinical outcomes: ratings and treatment effects at end point.









Mean (95% CI) P
Positive symptoms 37 18.0 (5.9) 10.9 (4.2) 39 15.3 (6.4) 12.3 (6.3) −2.5 (−4.7, −0.4) 0.02
Negative symptoms 37 16.5 (4.6) 12.0 (3.4) 39 14.7 (3.7) 12.1 (3.8) −0.4 (−2.0, 1.3) 0.64
General psychopathology 37 30.0 (7.9) 22.3 (4.9) 39 27.8 (4.2) 24.0 (6.0) −2.3 (−4.7, 0.1) 0.06
PANSS total score 37 64.0 (15.5) 45.2 (10.2) 39 57.8 (10.4) 48.4 (13.6) −5.3 (−10.6, −0.1) 0.05
Clinical Global Impression 37 4.4 (0.8) 3.3 (0.9) 39 4.3 (0.70) 3.6 (1.1) −0.3 (−0.8, 0.1) 0.13
Global Assessment of Functioning Scale 37 5.6 (1.0) 4.2 (1.0) 39 5.3 (1.1) 4.5 (1.2) −0.5 (−1.0, 0.0) 0.03
Social Functioning Scale 37 82.6 (25.3) 103.7 (26.6) 39 85.6 (27.1) 95.7 (26.9) 8.8 (−2.4, 20.0) 0.11
SAI: total score 37 8.0 (5.0) 11.9 (4.3) 39 7.2 (5.2) 10.6 (4.2) 1.0 (−0.8, 2.8) 0.26
EQ-5D: VAS 37 58.1 (28.4) 65.5 (24.8) 39 61.8 (27.5) 67.6 (23.0) −1.6 (−12.5, 9.4) 0.78
C-reactive proteina 36 6 [5,6] 6 [6, 6] 36 6 [6, 6] 6 [6, 6] 1.02 [0.97, 1.07] 0.40
White cell count (/ml) 37 6911 (1739) 6802 (1702)b 39 7033 (2169) 7227 (1845)b −419 (−1170, 333) 0.13
PANSS Positive and Negative Syndrome Scale, SAI Schedule of Assessment for Insight, EQ-5D VAS EuroQol-5D Visual Analogue Scale.
aDue to a skewed distribution, median [inter-quartile range] reported at each timepoint, along with ratio of values between groups [95% CI].
bTwo in each group refused final blood sample.
Table 3 Cognitive function: treatment effects at end point.









Mean (95% CI) P
Stroop Test Word (s) 24 141 (65) 112 (50) 27 120 (62) 101 (43) 1 (−20, 22) 0.91
Stroop Test Colour (s) 35 235 (165) 185 (87) 36 223 (93) 179 (56) 3 (−27, 33) 0.84
Difference in time (s) 23 110 (99) 97 (64) 27 97 (64) 71 (43) 21 (−4,47) 0.09
Block design (accuracy) 37 4.9 (8.2) 7.6 (8.6) 39 7.3 (7.8) 11.0 (10.0) −1.5 (−4.5, 1.6) 0.35
Oral fluency (words) 37 3.4 (3.6) 3.0 (2.7) 39 4.1 (5.7) 3.2 (3.0) −0.1 (−1.4,1.2) 0.91
Oral fluency (categories) 37 18.6 (5.9) 20.0 (5.8) 39 18.1 (6.6) 21.4 (4.9) −1.6 (−3.7, 0.6) 0.15
Coughlan learning tasks (verbal; items recalled) 37 34.3 (14.2) 38.9 (16.2) 39 30.3 (11.0) 39.6 (14.8) −3.5 (−9.4, 2.3) 0.23
Coughlan learning task (visual; items recalled) 36 16.8 (9.9) 24.7 (12.0) 37 20.1 (11.5) 24.3 (14.2) 2.5 (−2.9,7.8) 0.36
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For example, activated astroglia secrete chemokines that
attract Treg cells into the brain parenchyma and in turn
Tregs reduce astrogliosis by secreting an epidermal growth
factor42. Recent studies using advanced cell-specific
expression profiling in human post-mortem brain suggest
that astroglial activation is present in schizophrenia whereas
microglial gene sets are not overexpressed43. We propose
that methotrexate may improve psychotic symptoms by
promoting Treg-mediated restraint of astroglial inflamma-
tion in schizophrenia. Better characterisation of Treg
function and cell-mediated immunity in schizophrenia is
essential for progress in immunological approaches to
therapy. Further studies with methotrexate will require
comprehensive immunophenotyping to minimise the
number exposed to a drug that can have serious side effects
and to identify responsive subtypes. New PET radioligands
that recognise the state of astroglial and microglial activa-
tion will play an increasingly import role in identifying
targets for immunomodulatory drugs11.
In summary, we report the first clinical trial of the
immunosuppressant drug methotrexate in patients with
schizophrenia and the first evidence that a drug with known
efficacy in autoimmune disorders with actions on cell-
mediated mechanisms, may be effective in reducing psy-
chotic symptoms. Further studies would appear to be fea-
sible and are necessary to identify whether methotrexate has
clinically important effects that outweigh the risks, such as
in treatment refractory illnesses, severe negative symptoms
or in patients with evidence of identifiable immune
abnormalities such as impaired Treg function.
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